戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 counts show the anti-inflammatory effects of salsalate.
2                                              Salsalate (3.5 g/d) or placebo orally over 30 months.
3 ly 2011) to 48 weeks of placebo (n = 140) or salsalate, 3.5 g/d (n = 146), in addition to current the
4                                              Salsalate, a nonacetylated prodrug of salicylate, has be
5                               In conclusion, salsalate activates BAT, presumably by directly activati
6 sgenic mouse model of FTD, administration of salsalate after disease onset inhibited p300 activity, l
7 ion could explain some beneficial effects of salsalate and aspirin in humans.
8 ents and no difference in change between the salsalate and placebo groups (mean difference, -1 mm3; 9
9 p300-induced tau acetylation is inhibited by salsalate and salicylate, which enhance tau turnover and
10                                We found that salsalate attenuated and reversed high-fat diet-induced
11 by synthetic derivatives such as aspirin and salsalate, both of which are rapidly broken down to sali
12 acid, and triglyceride levels decreased with salsalate, but weight and low-density lipoprotein choles
13 ved in these beneficial metabolic effects of salsalate by treating mice with salsalate during and aft
14  of a second transcription factor inhibitor, salsalate, did not change this result.
15       Mild hypoglycemia was more common with salsalate; documented events occurred only in patients t
16 kout (AMPK-beta1KO) mice were treated with a salsalate dose resulting in clinically relevant serum sa
17 c effects of salsalate by treating mice with salsalate during and after development of high-fat diet-
18 ufficient to warrant recommending the use of salsalate for type 2 diabetes at this time.
19   One hundred ninety participants (89 in the salsalate group and 101 in the placebo group) completed
20 , and bilirubin levels were decreased in the salsalate group compared with the placebo group, while h
21 s and atrial arrhythmias more common, in the salsalate group compared with the placebo group.
22 c level over 48 weeks was 0.37% lower in the salsalate group than in the placebo group (95% CI, -0.53
23 rine albumin concentrations increased in all salsalate groups compared with placebo.
24 s of glycemic control also improved in the 3 salsalate groups, as did circulating triglyceride and ad
25                       The salicylate prodrug salsalate has been shown to improve metabolic parameters
26 indicate that the primary mechanism by which salsalate improves glucose homeostasis and NAFLD is via
27                                              Salsalate improves glucose intolerance and dyslipidemia
28                                              Salsalate improves glycemia in patients with T2DM and de
29             Short-duration studies show that salsalate improves glycemia in type 2 diabetes mellitus
30          In the Targeting Inflammation Using Salsalate in Cardiovascular Disease (TINSAL-CVD) trial p
31 were randomly assigned to receive placebo or salsalate in dosages of 3.0, 3.5, or 4.0 g/d for 14 week
32 cient to determine long-term risk-benefit of salsalate in T2DM.
33                                              Salsalate increased brachial artery flow-mediated dilati
34                                              Salsalate increased expression of the inhibitor of NF-ka
35 of differentiated T37i brown adipocytes with salsalate increased uncoupled respiration.
36                                              Salsalate is a dimeric form of salicylic acid that has b
37                                              Salsalate is a prodrug of salicylate that lowers blood g
38                                              Salsalate lowers HbA1c levels and improves other markers
39                   These results suggest that salsalate may be useful in reducing vascular injury and
40  fifty-seven participants were randomized to salsalate (n = 129) or placebo (n = 128).
41 articipants were analyzed (placebo, n = 137; salsalate, n = 146).
42                                              Salsalate (nonacetylated salicylate, 4500 mg/d), a compo
43 f this study is to investigate the effect of salsalate on vascular injury and repair in a rat model o
44                       However, the effect of salsalate on vascular injury has not been determined.
45                     The beneficial effect of salsalate on vascular injury was associated with upregul
46 d patients receiving the p300/CBP inhibitors salsalate or diflunisal exhibit decreased incidence of A
47 ns reached in plasma after administration of salsalate or of aspirin at high doses, salicylate activa
48  23, 2008, and July 5, 2012, to 30 months of salsalate or placebo in addition to standard, guideline-
49 ation during placebo (P<0.001) but not after salsalate (P=0.23).
50 tions in concomitant diabetes medications in salsalate recipients than in placebo recipients.
51                                      In men, salsalate reduced 11beta-HSD1 expression in subcutaneous
52                                              Salsalate reduced nitrotyrosine (P=0.06) and expression
53 ates AMPK via the beta1 subunit, but whether salsalate requires AMPK-beta1 to improve T2D and NAFLD h
54                             Mechanistically, salsalate selectively promoted the uptake of fatty acids
55                               Treatment with salsalate significantly decreased the intima-to-media ra
56                                              Salsalate treatment decreased total white blood cell, ly
57                 The present study shows that salsalate treatment decreases vascular damage caused by
58      Higher proportions of patients in the 3 salsalate treatment groups experienced decreases in HbA1
59                                              Salsalate treatment increased VO2, lowered fasting gluco
60                                              Salsalate treatment was started in female Zucker fatty r
61 L, P< or =0.0001 versus placebo) by day 4 of salsalate treatment.
62                                    Moreover, salsalate upregulated Ucp1 expression and enhanced glyce
63                 Two weeks' administration of salsalate was also investigated in a randomized double-b
64  brachial artery flow-mediated dilation with salsalate was inversely related to baseline flow-mediate
65   The tau-lowering and protective effects of salsalate were diminished in neurons expressing K174Q ta
66                                              Salsalate when added to current therapies that include a